SRT Therapeutics is a San Diego-based biotech company established in 2024 by the founders of Prometheus Biosciences, Steph Targan, MD (Cedars Sinai), Janine Bilsborough, Ph.D. (Cedars Sinai), the scientific team that discovered Tulisokibart (MK7240) and the role of TL1A in IBD and Scott Glenn and Lauren Otsuki, the drug development team that took Tulisokibart (MK7240) from academia into the clinic. Building on the demonstrated success of the precision medicine approach in IBD with Tulisokibart, SRT Therapeutics will expand this approach by targeting key pathways that not only modulate inflammatory pathways, but also promote tissue healing in IBD. This strategy will move SRT Therapeutics beyond the current empirical treatment model to realize the goal of enhancing both outcomes and the quality of care for our patients.

SRT Therapeutics Inc.

Org chart

Teams

Offices